Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer

Trial Profile

An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Nivolumab (Primary) ; Pixatimod (Primary)
  • Indications Adrenocortical carcinoma; Colorectal cancer; Endometrial cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Uterine cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Nov 2018 Preliminary results (n=9 data cut off: 19, June 2018) presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    • 24 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top